Trend
DailyUptrend (starting)
4 hourDescending Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $9.39
Key levels
Resistance$13.46
Resistance$12.12
Support$11.16
Support$9.39
Latest news & SEC filings
AnalystHC Wainwright Keeps $36 Target and Buy Rating on 4D Molecular
All FDMT news →4D Molecular Therapeutics is a clinical-stage biotechnology company that designs gene-based medicines using customized viral vectors developed through its own discovery platform. Its main candidate, 4D-150, is being tested in late-stage trials for two retinal blood vessel conditions affecting the back of the eye. Additional programs address lung disease, including a treatment for cystic fibrosis being developed with foundation funding, and an earlier-stage candidate for a inherited lung condition.
Based on the company's 10-K filed Mar 18, 2026.
Nasdaq · Healthcare
SEPT Low Target
$20.00
SEPT Mid Target
$33.00
SEPT High Target
$37.00
Analyst Consensus
$33.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for FDMT.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$28.49
27
Moat Score
NONE
3/9
Piotroski Score
5.3
Altman Z-Score
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bizily Scott | officer | Buy | 1,635 | $7K | Oct 16, 2026 |
| Bizily Scott | officer | Sale | 1,635 | $21K | Oct 16, 2026 |
| Kirn David | director officer | Sale | 58,061 | $750K | Oct 5, 2026 |
| Kirn David | director officer | Sale | 272 | $4K | Oct 5, 2026 |
| Bizily Scott | officer | Buy | 1,635 | $7K | Sep 16, 2026 |
| Bizily Scott | officer | Sale | 1,635 | $22K | Sep 16, 2026 |
| Kirn David | director officer | Sale | 1,922 | $19K | Jun 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
230194.6%
3yr Revenue CAGR
200.9%
EPS Growth YoY
18.79%
FCF Growth YoY
20.8%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for FDMT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:03:26 | $12.99 | 9,969 | $$129K | SELL |
| 21:00:17 | $12.99 | 1,500 | $$19K | BUY |
| 20:58:15 | $13.01 | 1,000 | $$13K | SELL |
| 20:57:00 | $12.96 | 1,100 | $$14K | BUY |
| 20:56:51 | $12.97 | 1,200 | $$16K | BUY |
5 dark pool trades shown · $$192K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for 4D Molecular Therapeutics, Inc. (FDMT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →4D Molecular Therapeutics, Inc. (FDMT) is at $12.12, down 6.74% (-$0.88) at the Nov 12, 2026 close.
Latest FDMT news — Oct 22, 2026: HC Wainwright Keeps $36 Target and Buy Rating on 4D Molecular
The average analyst price target for FDMT is $33.00, ranging from $20 to $37, based on 5 analysts.
Analyst ratings for FDMT: 1 Buy, 4 Hold, 0 Sell — consensus Hold.
FDMT last reported on Aug 13, 2026: EPS -$1.04 vs -$1.06 expected — a beat of 1.9%.
FDMT does not currently pay a dividend.
Support: $11.16, $9.39, $8.37. Resistance: $12.12, $13.46, $14.98.
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
Oct 22, 2026: HC Wainwright Keeps $36 Target and Buy Rating on 4D Molecular